177 related articles for article (PubMed ID: 18706341)
1. [Viral safety of biologicals].
Barin F
Ann Pharm Fr; 2008 Jun; 66(3):129-39. PubMed ID: 18706341
[TBL] [Abstract][Full Text] [Related]
2. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
3. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
4. [Viruses and unconventional transmissible agents: update on transmission via blood ].
Barin F
Transfus Clin Biol; 2000 Jun; 7 Suppl 1():5s-10s. PubMed ID: 10919217
[TBL] [Abstract][Full Text] [Related]
5. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
6. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
Gröner A
Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
[TBL] [Abstract][Full Text] [Related]
7. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
Hilfenhaus J; Gröner A; Nowak T; Weimer T
Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
[TBL] [Abstract][Full Text] [Related]
8. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
Hilfenhaus J; Niedrig M; Nowak T
Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
10. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
11. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
12. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
13. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
14. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
15. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
16. Parvovirus B19 DNA in plasma pools and plasma derivatives.
Schmidt I; Blümel J; Seitz H; Willkommen H; Löwer J
Vox Sang; 2001 Nov; 81(4):228-35. PubMed ID: 11903998
[TBL] [Abstract][Full Text] [Related]
17. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
18. Safety procedures of coagulation factors.
Jorquera JI
Haemophilia; 2007 Dec; 13 Suppl 5(Suppl 5):41-6. PubMed ID: 18078396
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
20. Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice--validation of virus removal and inactivation.
Trijzelaar B
Biotherapy; 1993; 6(2):93-102. PubMed ID: 8398576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]